NYSE:PFE 9 August 2025 - 2 April 2026

GSK Wins Court Ruling in Pfizer-BioNTech Covid Vaccine Patent Fight
······

GSK Wins Court Ruling in Pfizer-BioNTech Covid Vaccine Patent Fight

A U.S. federal judge has tossed Acuitas Therapeutics Inc.’s attempt to shield Pfizer and BioNTech’s Comirnaty Covid-19 vaccine from GSK’s patent claims, handing the British pharma giant a procedural victory in the ongoing mRNA legal fight. Judge Gregory B. Williams sided with GSK, dismissing the Acuitas case on grounds that the court lacked subject-matter jurisdiction—essentially, it didn’t have the authority to weigh in as presented, according to Bloomberg Law on Friday. The decision keeps the spotlight fixed on the main Delaware showdown involving GSK, Pfizer and BioNTech, instead of letting a supplier-driven lawsuit muddy the waters. Back in 2024, GSK filed suit against Pfizer and BioNTech, claiming Comirnaty stepped on patents for mRNA vaccine technology the company says it created
May 9, 2026
GSK plc simplifies ViiV Healthcare ownership as Pfizer exits and Shionogi raises stake
·······

GSK plc simplifies ViiV Healthcare ownership as Pfizer exits and Shionogi raises stake

GSK plc wrapped up changes to ViiV Healthcare’s ownership structure on April 1. After Pfizer’s exit from the HIV-focused joint venture, Japan’s Shionogi bumped its stake up to 21.7%. GSK remains the majority owner with 78.3%, the company said. Timing is crucial here: ViiV is a core growth driver as GSK shifts focus toward specialty medicines. For 2025, GSK reported an 11% increase in HIV sales to 7.7 billion pounds, fueling a 17% jump in specialty medicines revenue.
April 2, 2026
Groundbreaking treatments - super crops - and a revolution in green technology
·········

Biotech 2025: Breakthrough Cures, Super Crops, and a Green Tech Revolution

The biotechnology industry is entering a new golden age in 2025, with innovations reshaping healthcare, agriculture, environmental management, and manufacturing. Globally, biotech is booming – the market is projected to expand from about $483 billion in 2024 to $546 billion in 2025, a robust growth rate of roughly 13% labiotech.eu. This rapid rise is fueled by game-changing advances: life-saving gene therapies and mRNA vaccines in medicine, gene-edited “super crops” boosting food security, and bio-based solutions that turn pollution into products. Major players from nimble startups to pharma giants are racing to commercialize breakthroughs, while investors pour capital into promising ventures. The public is increasingly seeing biotechnology’s impact everywhere – from the doctor’s office to the dinner plate – making 2025
August 9, 2025